Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$136.84 USD

136.84
1,508,925

+0.32 (0.23%)

Updated Aug 4, 2025 01:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Kevin Cook headshot

The $200 Club: Will Facebook Beat Alibaba There First?

by Kevin Cook

When you find great fundamental growth stories that institutions must own, you can buy and trade them for a long time in a bull market.

    Zacks Equity Research

    CVS Health Grows on Specialty Pharmacy amid Retail Woes

    by Zacks Equity Research

    CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.

      Zacks Equity Research

      Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down

      by Zacks Equity Research

      Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.

        Zacks Equity Research

        Haemonetics Banks on Solid Plasma & Haemonetics Management

        by Zacks Equity Research

        Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).

          Zacks Equity Research

          Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4

          by Zacks Equity Research

          Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.

            Zacks Equity Research

            Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat

            by Zacks Equity Research

            Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.

              Zacks Equity Research

              Focus on These 5 Top-Ranked Profitable Stocks in August

              by Zacks Equity Research

              Higher net income ratio usually implies a company's ability to generate ample revenue and successfully manage all its business functions.

                Zacks Equity Research

                STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up

                by Zacks Equity Research

                STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.

                  Zacks Equity Research

                  BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

                  by Zacks Equity Research

                  BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.

                    Zacks Equity Research

                    BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates

                    by Zacks Equity Research

                    BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.

                      Zacks Equity Research

                      Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

                      by Zacks Equity Research

                      Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                        Zacks Equity Research

                        Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2

                        by Zacks Equity Research

                        Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.

                          Zacks Equity Research

                          CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed

                          by Zacks Equity Research

                          CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.

                            Zacks Equity Research

                            Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact

                            by Zacks Equity Research

                            Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.

                              Zacks Equity Research

                              Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2

                              by Zacks Equity Research

                              Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.

                                Zacks Equity Research

                                Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates

                                by Zacks Equity Research

                                Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.

                                  Zacks Equity Research

                                  Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines

                                  by Zacks Equity Research

                                  Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.

                                    Zacks Equity Research

                                    Cardiovascular Systems Rides on Innovation Amid Several Woes

                                    by Zacks Equity Research

                                    Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.

                                      Zacks Equity Research

                                      Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss

                                      by Zacks Equity Research

                                      Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.

                                        Zacks Equity Research

                                        Wright Medical Group (WMGI) Q2 Loss Narrower than Expected

                                        by Zacks Equity Research

                                        Wright Medical Group N.V. (WMGI) posted narrower-than-expected loss on account of strong growth in the U.S.

                                          Zacks Equity Research

                                          Inogen (INGN) Beats Earnings and Revenue Estimates in Q2

                                          by Zacks Equity Research

                                          Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.

                                            Zacks Equity Research

                                            Illumina (ILMN) Rides on New Products, Low Margin a Concern

                                            by Zacks Equity Research

                                            Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.

                                              Zacks Equity Research

                                              Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up

                                              by Zacks Equity Research

                                              Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.

                                                Kevin Cook headshot

                                                Bull of the Day: Align Technology (ALGN)

                                                by Kevin Cook

                                                The clear winner in alternative dental alignment continues to make long-term investors smile

                                                  Zacks Equity Research

                                                  Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance

                                                  by Zacks Equity Research

                                                  Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.